• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka.根据欧洲狼疮治疗方案管理的一组狼疮性肾炎患者的临床病理特征、治疗反应及长期预后的预测因素:斯里兰卡的一项回顾性分析
BMC Res Notes. 2017 Feb 2;10(1):80. doi: 10.1186/s13104-017-2402-6.
2
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.免疫抑制治疗的早期反应可预测狼疮性肾炎的良好肾脏结局:来自欧洲狼疮性肾炎试验患者长期随访的经验教训。
Arthritis Rheum. 2004 Dec;50(12):3934-40. doi: 10.1002/art.20666.
3
Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.狼疮肾炎患者接受利妥昔单抗治疗的长期随访--临床和组织病理学应答。
Rheumatology (Oxford). 2013 May;52(5):847-55. doi: 10.1093/rheumatology/kes348. Epub 2013 Jan 3.
4
The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.经活检证实的中国患者狼疮性肾炎的预后:86例长期随访
Chin Med J (Engl). 1997 Jul;110(7):502-7.
5
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.他克莫司与霉酚酸酯治疗狼疮性肾炎诱导缓解的随机对照试验及长期随访
Ann Rheum Dis. 2016 Jan;75(1):30-6. doi: 10.1136/annrheumdis-2014-206456. Epub 2014 Dec 30.
6
Clinicopathological and outcome analysis of adult lupus nephritis patients in China.中国成人狼疮性肾炎患者的临床病理及预后分析
Int Urol Nephrol. 2015 Mar;47(3):513-20. doi: 10.1007/s11255-014-0903-y. Epub 2015 Jan 7.
7
Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.利妥昔单抗治疗耐药性狼疮肾炎:快速进展性新月体性狼疮肾炎治疗失败。
Lupus. 2013 May;22(6):574-82. doi: 10.1177/0961203313483376. Epub 2013 Apr 30.
8
Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone.弥漫性增殖性和膜性狼疮性肾炎的序贯治疗:环磷酰胺和泼尼松龙,随后是硫唑嘌呤和泼尼松龙。
Nephron. 1995;71(3):321-7. doi: 10.1159/000188739.
9
Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.西班牙裔人群狼疮性肾炎诱导治疗的比较:单中心队列分析
J Rheumatol. 2015 Nov;42(11):2082-91. doi: 10.3899/jrheum.150395. Epub 2015 Sep 15.
10
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.狼疮性肾炎的免疫抑制治疗:欧洲狼疮性肾炎试验,一项低剂量与高剂量静脉注射环磷酰胺的随机试验。
Arthritis Rheum. 2002 Aug;46(8):2121-31. doi: 10.1002/art.10461.

引用本文的文献

1
Acute Kidney injury of glomerular origin in Asian population: Causes and outcomes - Meta-Analysis.亚洲人群中肾小球源性急性肾损伤:病因与结局 - 荟萃分析
Pak J Med Sci. 2025 May;41(5):1536-1545. doi: 10.12669/pjms.41.5.11858.
2
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America.在北美,使用 EuroLupus 环磷酰胺剂量治疗儿童发病系统性红斑狼疮狼疮性肾炎。
J Rheumatol. 2022 Jun;49(6):607-614. doi: 10.3899/jrheum.210428. Epub 2022 Feb 15.
3
Calcineurin Inhibitors in the Treatment of Lupus Nephritis: A Hare Versus Turtle Story?钙调神经磷酸酶抑制剂治疗狼疮性肾炎:龟兔赛跑的故事?
J Am Soc Nephrol. 2017 Dec;28(12):3435-3437. doi: 10.1681/ASN.2017080830. Epub 2017 Oct 5.

本文引用的文献

1
Long-term outcome of lupus nephritis in Asian Indians.亚洲印第安人狼疮肾炎的长期预后。
Arthritis Care Res (Hoboken). 2012 May;64(5):713-20. doi: 10.1002/acr.21597.
2
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.1995年至2006年美国狼疮性肾炎所致终末期肾病的发病率、人口统计学特征及转归趋势
Arthritis Rheum. 2011 Jun;63(6):1681-8. doi: 10.1002/art.30293.
3
Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus.系统性红斑狼疮导致的终末期肾病的就诊情况和发病率。
J Rheumatol. 2010 Jun;37(6):1158-63. doi: 10.3899/jrheum.091199. Epub 2010 Apr 15.
4
Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis.100 例狼疮肾炎患者队列的长期死亡率和肾脏结局。
Arthritis Care Res (Hoboken). 2010 Jun;62(6):873-80. doi: 10.1002/acr.20116.
5
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.Euro-Lupus Nephritis Trial 比较低剂量和高剂量静脉注射环磷酰胺的 10 年随访数据。
Ann Rheum Dis. 2010 Jan;69(1):61-4. doi: 10.1136/ard.2008.102533.
6
The long-term outcome of 93 patients with proliferative lupus nephritis.93例增殖性狼疮性肾炎患者的长期预后。
Nephrol Dial Transplant. 2007 Sep;22(9):2531-9. doi: 10.1093/ndt/gfm245. Epub 2007 May 17.
7
Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.霉酚酸酯作为弥漫性增殖性狼疮性肾炎持续诱导和维持治疗的长期研究。
J Am Soc Nephrol. 2005 Apr;16(4):1076-84. doi: 10.1681/ASN.2004080686. Epub 2005 Feb 23.
8
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.免疫抑制治疗的早期反应可预测狼疮性肾炎的良好肾脏结局:来自欧洲狼疮性肾炎试验患者长期随访的经验教训。
Arthritis Rheum. 2004 Dec;50(12):3934-40. doi: 10.1002/art.20666.
9
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.狼疮性肾炎的免疫抑制治疗:欧洲狼疮性肾炎试验,一项低剂量与高剂量静脉注射环磷酰胺的随机试验。
Arthritis Rheum. 2002 Aug;46(8):2121-31. doi: 10.1002/art.10461.
10
Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.序贯口服环磷酰胺和硫唑嘌呤治疗弥漫性增殖性狼疮性肾炎的疗效及预后指标
Arthritis Rheum. 2002 Apr;46(4):1003-13. doi: 10.1002/art.10138.

根据欧洲狼疮治疗方案管理的一组狼疮性肾炎患者的临床病理特征、治疗反应及长期预后的预测因素:斯里兰卡的一项回顾性分析

Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka.

作者信息

Herath Nalaka, Ratnatunga Neelakanthi, Weerakoon Kosala, Wazil Abdul, Nanayakkara Nishantha

机构信息

Nephrology Unit, Teaching Hospital, Karapitiya, Galle, Sri Lanka.

Department of Pathology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka.

出版信息

BMC Res Notes. 2017 Feb 2;10(1):80. doi: 10.1186/s13104-017-2402-6.

DOI:10.1186/s13104-017-2402-6
PMID:28148285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5288939/
Abstract

BACKGROUND

Despite the improvement in survival of patients with lupus nephritis (LN) globally, there is sparse data from Sri Lanka (SL). The current study aims to describe the clinicopathological findings, treatment response and predictors of long-term outcome of patients with WHO class III-IV LN in SL, managed according to the Euro-lupus regime.

RESULTS

Of 72 patients, 64 were females. In half of them, LN was diagnosed within the 1st year of the illness. The most common presenting feature was sub-nephrotic proteinuria. Sixteen and twenty patients had nephrotic syndrome and abnormal renal function respectively at the time of diagnosis. Fifty-four patients (75%) responded to the Euro-lupus regimen [CR, 20 (28%); PR, 34(47%)]. Later at 6 months, 65 patients (90%) achieved remission [CR, 31(43%); PR, 34 (47%)]. Seven patients experienced treatment failure. During the total duration of follow up, 54 patients remained in complete or partial remission, 26 developed renal relapses, and 19 suffered severe infective episodes. Renal relapses were more common in people who achieved partial remission than complete remission. The long term renal outcome was not associated with age, sex, severity of proteinuria, class of LN or initial renal function. Patients who achieved remission at 6 months had a good long-term outcome.

CONCLUSIONS

The demographic and clinical features of WHO class III and IV LN in Sri Lankan patients were similar to that reported in the global literature. 75% of patients responded to the Euro-lupus regimen. Therefore, this regime is a suitable initial regimen for LN patients in SL. Good long-term renal outcome can be predicted by early response to therapy. Further studies are necessary to explore better treatment options for patients who fail to achieve remission during initial therapy.

摘要

背景

尽管全球狼疮性肾炎(LN)患者的生存率有所提高,但来自斯里兰卡(SL)的数据却很少。本研究旨在描述斯里兰卡按照欧洲狼疮治疗方案管理的WHO III-IV级LN患者的临床病理特征、治疗反应及长期预后的预测因素。

结果

72例患者中,64例为女性。其中一半患者在发病第1年内被诊断为LN。最常见的表现特征是亚肾病范围蛋白尿。诊断时分别有16例和20例患者患有肾病综合征和肾功能异常。54例患者(75%)对欧洲狼疮治疗方案有反应[完全缓解(CR),20例(28%);部分缓解(PR),34例(47%)]。6个月后,65例患者(90%)实现缓解[CR,31例(43%);PR,34例(47%)]。7例患者治疗失败。在整个随访期间,54例患者保持完全或部分缓解,26例出现肾脏复发,19例发生严重感染事件。部分缓解的患者比完全缓解的患者肾脏复发更常见。长期肾脏预后与年龄、性别、蛋白尿严重程度、LN分级或初始肾功能无关。6个月时实现缓解的患者长期预后良好。

结论

斯里兰卡患者中WHO III级和IV级LN的人口统计学和临床特征与全球文献报道相似。75%的患者对欧洲狼疮治疗方案有反应。因此,该方案是斯里兰卡LN患者合适的初始治疗方案。早期治疗反应可预测良好的长期肾脏预后。有必要进一步研究,为初始治疗未实现缓解的患者探索更好的治疗选择。